Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEAUK5)

Drug Name
CALCEOLARIOSIDE B Drug Info
Synonyms
Calceolarioside B; 105471-98-5; Calceorioside B; CHEMBL518414; CHEBI:68345; Nuomioside A; Calceolarioside-B; AC1NRV68; MEGxp0_000508; ACon1_000407; DTXSID70414938; MolPort-001-740-673; ZINC14512219; BDBM50269516; AKOS016010662; MCULE-4912944466; NCGC00169106-01; AJ-64948; KB-279900; ST24046273; Y0045; 3,4-Dihydroxyphenethyl 6-O-[3-(3,4-dihydroxyphenyl)propenoyl]-beta-D-glucopyranoside; NCGC00169106-02![(2R,3S,4S,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-3,4,5-trihydroxyoxan-2-yl]methyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5273567
ChEBI ID
CHEBI:68345
CAS Number
CAS 105471-98-5
TTD Drug ID
DMEAUK5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Protein kinase C alpha (PRKCA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sodium phenylbutyrate DMXLBCQ Spinal muscular atrophy 8B61 Approved [2]
Sotrastaurin acetate DME53YS Renal transplantation NE84 Phase 2 [3]
PMID28460551-Compound-3 DMA1FRM N. A. N. A. Patented [4]
ISIS 3521 DMZFS69 N. A. N. A. Discontinued in Phase 2 [5]
BALANOL DMDLN9E N. A. N. A. Terminated [6]
RO-320432 DMFZ1YW N. A. N. A. Terminated [7]
LY-317644 DMM20PI N. A. N. A. Terminated [8]
Acteoside DM0YHKB Nephritis GB40 Terminated [1]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [9]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Protein kinase C alpha (PRKCA) TTFJ8Q1 KPCA_HUMAN Inhibitor [1]

References

1 Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2.
2 Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401.
3 Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
4 Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
5 Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.Lung Cancer.2006 May;52(2):173-80.
6 Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
7 Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
8 Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
9 Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
10 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.